28525838|t|Design, synthesis and evaluation of azaacridine derivatives as dual-target EGFR and Src kinase inhibitors for antitumor treatment
28525838|a|Overexpression of EGFR is often associated with advanced stage disease and poor prognosis. In certain cancers, Src works synergistically with EGFR to promote proliferation, survival, invasion and metastasis. Development of dual-target drugs against EGFR and Src is of therapeutic advantage against these cancers. Based on molecular docking and our previous studies, we rationally designed a new series of azaacridine derivatives as potent EGFR and Src dual inhibitors. Most of the synthesized azaacridines displayed good antiproliferative activity against K562 and A549 cells. The representative compound 13b showed nM IC50 values against K562 and A549 cells, and inhibited EGFR at inhibition rate of 33.53% at 10 μM and Src at inhibition rate of 72.12% at 1 μM. Furthermore, compound 13b could inhibit the expression of EGFR, p-EGFR, Src and p-Src. Moreover, 13b efficiently inhibited the invasion of tumor cells and induced cancer cells apoptosis. Our study suggested that azaacridine scaffold can be developed as novel multi-target kinase inhibitors for cancer therapy.
28525838	36	59	azaacridine derivatives	T103	UMLS:C0001186
28525838	75	79	EGFR	T103	UMLS:C0034802
28525838	84	94	Src kinase	T103	UMLS:C0282625
28525838	95	105	inhibitors	T103	UMLS:C3537035
28525838	120	129	treatment	T058	UMLS:C0087111
28525838	130	144	Overexpression	T038	UMLS:C1514559
28525838	148	152	EGFR	T103	UMLS:C0034802
28525838	193	200	disease	T038	UMLS:C0012634
28525838	205	219	poor prognosis	T033	UMLS:C0278252
28525838	232	239	cancers	T038	UMLS:C0007097
28525838	241	244	Src	T103	UMLS:C0282625
28525838	272	276	EGFR	T103	UMLS:C0034802
28525838	288	301	proliferation	T038	UMLS:C0596290
28525838	303	311	survival	T038	UMLS:C0007620
28525838	313	321	invasion	T038	UMLS:C2699153
28525838	326	336	metastasis	T038	UMLS:C4255448
28525838	365	370	drugs	T103	UMLS:C0013227
28525838	379	383	EGFR	T103	UMLS:C0034802
28525838	388	391	Src	T103	UMLS:C0282625
28525838	434	441	cancers	T038	UMLS:C0007097
28525838	452	469	molecular docking	T170	UMLS:C3494274
28525838	487	494	studies	T062	UMLS:C2603343
28525838	535	558	azaacridine derivatives	T103	UMLS:C0001186
28525838	569	573	EGFR	T103	UMLS:C0034802
28525838	578	581	Src	T103	UMLS:C0282625
28525838	587	597	inhibitors	T103	UMLS:C3537035
28525838	623	635	azaacridines	T103	UMLS:C0001186
28525838	686	690	K562	T017	UMLS:C0600432
28525838	695	705	A549 cells	T017	UMLS:C4277577
28525838	726	738	compound 13b	T103	UMLS:C1254351
28525838	769	773	K562	T017	UMLS:C0600432
28525838	778	788	A549 cells	T017	UMLS:C4277577
28525838	804	808	EGFR	T103	UMLS:C0034802
28525838	851	854	Src	T103	UMLS:C0282625
28525838	906	918	compound 13b	T103	UMLS:C1254351
28525838	937	947	expression	T038	UMLS:C1171362
28525838	951	955	EGFR	T103	UMLS:C0034802
28525838	957	963	p-EGFR	T103	UMLS:C0034802
28525838	965	968	Src	T103	UMLS:C0282625
28525838	973	978	p-Src	T103	UMLS:C0282625
28525838	990	993	13b	T103	UMLS:C1254351
28525838	1020	1043	invasion of tumor cells	T033	UMLS:C1269955
28525838	1056	1068	cancer cells	T017	UMLS:C0334227
28525838	1069	1078	apoptosis	T038	UMLS:C0162638
28525838	1084	1089	study	T062	UMLS:C2603343
28525838	1105	1116	azaacridine	T103	UMLS:C0001186
28525838	1152	1182	multi-target kinase inhibitors	T103	UMLS:C3537035
28525838	1187	1201	cancer therapy	T058	UMLS:C0920425